TORONTO, July 12, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announces the following:
Biosign Begins Television Advertising
The Company is pleased to announce that a new television advertising
campaign will launch on Monday July 15th, 2013. Biosign will run television ads for the Pulsewave™ Health
Monitor in multiple markets including St John, Fredericton & Moncton,
NB as well as Toronto ON, on the Rogers TV Listings Channel. A
30-second spot will highlight the most important features of the
Pulsewave™ system, including the fact that Pulsewave™ is the only
approved, over-the-counter system that allows the user to see their
heart beat in real time on the computer screen.
Biosign is embarking on a sustained television advertising program for
Pulsewave™, initially in Canada with campaigns in the United States to
follow. Rogers Digital Cable television enables the Company to target
ads to specific municipalities, making it easy to control costs. The ad
campaign will be evaluated on a weekly basis, tracking the amount of
website traffic created as well as more traditional measures including
sales and enquiries. The intention is to use the selectivity of digital
cable to test various versions of each ad, in order to maximize the
impact of each campaign. The first ads will push Pulsewave buyers to
the Biosign web store. Later ads will test the results gained by
pushing buyers to live operators as compared to website buyers.
Rogers Digital Cable reaches 3 million Eastern Canadian households,
while in Western Canada the major provider is Shaw Digital Cable.
Biosign intends to advertise with both providers. Through this program,
Biosign expects to sell an increasing number of Pulsewave units
throughout the summer and autumn of 2013.
Biosign CEO Robert Kaul commented, "The launch of our first television
advertising campaign is extremely important. For the first time,
Biosign has taken steps to communicate the benefits of our easy-to-use
technology directly to consumers. Direct-to-consumer sales offers
higher margins and the ability to control the consumer experience,
which means we can deliver superior customer service. Along with our
previously announced professional software integration projects (for
example ClinicServer & QLINE), our direct-to-consumer program completes
the Biosign go-to-market strategy."
Biosign closes private placement
On July 4th, 2013, the Company closed a private placement for 17,852,571 units of
the Company (the "Units") at an average purchase price of $0.028 per
Unit. Each Unit is comprised of one common share and one common share
purchase warrant. Each common share purchase warrant is exercisable for
a 2-year period at $0.05 per share during the first twelve months and
$0.10 per share in the second twelve months. The securities issued in
connection with the Offering are subject to a four-month-and-one-day
hold period from the issuance date in accordance with the policies of
the TSXV and applicable securities laws. No director, officer or other
insider purchased any Units pursuant to the private placement. The
private placement was executed under the TSX Venture Exchange's
temporary relief program, which permitted reporting issuers to raise up
to $500,000 under such provisions.
Former Director receives shares to satisfy indebtedness.
Pursuant to TSXV approval issued on March 12, 2013, a former director
was issued 500,000 shares at a deemed value of $0.10 to settle
outstanding indebtedness. These shares shall be subject to a hold
period of four months plus one day from the date of issuance.
About Biosign Technologies Inc:
Biosign Technologies Inc. (TSXV: BIO) provides automated, software
enabled health information solutions. Key solutions include the Pulsewave™ Health Monitor and the Healthanywhere™ Patient monitoring / self-care platform. The Company's Pulsewave™
Health Monitor solution enables Pulse data collection for
cardiovascular clinical decision support, and self-care, while its
Healthanywhere™ solution offers industry-leading remote patient
monitoring, and patient centred care management . The Company also
offers a number of cardiovascular screening programs for consumers
under its Heart Friendly™ brand, including Heart Friendly™ Practice,
Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more
information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in the company's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Chief Executive Officer
Biosign Technologies Inc
Phone: (416) 218-9800 ext. 201